AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

NCT05302336 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

402

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Chemotherapeutic Toxicity

Interventions

DRUG: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University